UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

000197 THE ANTI-IDIOTYPIC MONOCLONAL ANTIBODY ACA125 IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PERITONEAL CANCER. A PHASE II TRIAL OF THE AGO-OVAR

International journal of gynecological cancer, 2005-09, Vol.15 (Suppl 2), p.106-106

2005

Volltextzugriff (PDF)

0189: Influence of Platinum-Based Chemotherapy On Disseminated Tumor Cells in Blood and Bone Marrow of Patients with Primary Ovarian Cancer

International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.653-654

2006

Volltextzugriff (PDF)

105Development of version 2.0 prostate-specific instrument for standardized health-related quality of life (HR-QoL) measurement based on the experience with version 1.0 protocol: Reliability testing and main component analysis

Radiotherapy and oncology, 2001, Vol.60, p.S29-S30

2001

Volltextzugriff (PDF)

1093 Local dose escalation using temporary interstitial source brachytherapy (high-dose-rate) for clinically localized prostate cancer: Long-term outcome in hormone naïve men

European journal of cancer supplements, 2003-09, Vol.1 (5), p.S327-S327

2003

Volltextzugriff (PDF)

114 CARTILAGE BIOMARKERS AFTER ACLT

Osteoarthritis and cartilage, 2008, Vol.16, p.S62-S62

2008

Volltextzugriff (PDF)

115 CARTILAGE BIOMARKERS AFTER MENISCECTOMY

Osteoarthritis and cartilage, 2008, Vol.16, p.S62-S62

2008

Volltextzugriff (PDF)

1168P Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined

Annals of oncology, 2023-10, Vol.34, p.S695-S695

2023

Volltextzugriff (PDF)

13-cis retinoic acid and interferon-alfa-2a as palliative therapy in pretreated, recurrent squamous epithelial carcinoma of the cervix uteri and vulva

Geburtshilfe und Frauenheilkunde, 1996-10, Vol.56 (10), p.520

1996

Volltextzugriff (PDF)

13-cis Retinolsäure und interferon α2 a als Palliativtherapie beim vorbehandelten, rezidivierenden Plattenepithelkarzinom der Zervix uteri und Vulva

Geburtshilfe und Frauenheilkunde, 1996-10, Vol.56 (10), p.520-524

1996

Volltextzugriff (PDF)

13-cis Retinolsäure und Interferon α2a als Palliativtherapie beim vorbehandelten, rezidivierenden Plattenepithelkarzinom der Zervix uteri und Vulva

Geburtshilfe und Frauenheilkunde, 1996-10, Vol.56 (10), p.520-524

1996

Volltextzugriff (PDF)

154 O - Intermediate analysis at minimum 5 years follow-up of 70 patients with prostate cancer treated by external beam and brachytherapy

European journal of cancer (1990), 1996, Vol.32, p.S30-S30

1996

Volltextzugriff (PDF)

16 Orbital rhabdomyosarcoma of the child: The role of PDR brachytherapy in eye preservation

Radiotherapy and oncology, 1996-05, Vol.39, p.S4-S4

1996

Volltextzugriff (PDF)

16 Peroperative eye-preserving interstitial PDR brachy-therapy (BT) for orbital tumors and malignancies involving the base of skull

Radiotherapy and oncology, 1998-05, Vol.47, p.S4-S4

1998

Volltextzugriff (PDF)

162 Fractionated peroperative interstitial HDR/PDR-brachytherapy using the plastic tube technique and conformal treatment planning: The Kiel experience

Radiotherapy and oncology, 1996-05, Vol.39, p.S41-S41

1996

Volltextzugriff (PDF)

172 Phase I/II study of PLD and carboplatin in patients with advanced gynaecological carcinomas. An interim analysis of the GYN II trial of the AGO ovarian cancer study group

European journal of cancer supplements, 2003-09, Vol.1 (5), p.S55-S55

2003

Volltextzugriff (PDF)

173 Does non invasive nodal staging and elective irradiation of the pelvic lymphatics compromise the feasibility of local dose escalation using high dose rate brachytherapy for increased curability in men with localized prostate cancer? Long-term results: Survival and toxicity

Radiotherapy and oncology, 2000-05, Vol.55, p.89-90

2000

Volltextzugriff (PDF)

2009 Prevalence of erectile dysfunction in men with prostate cancer (PCa) prior to definitive radiotherapy: a prospective assessment

European journal of cancer supplements, 2009, Vol.7 (2), p.154-154

2009

Volltextzugriff (PDF)

21 Peroperative interstitial pdrfhdr-brachytherapy (BT) for rectal cancer recurrences or non curative resected primaries: Experience with 32 patients

Radiotherapy and oncology, 1998-05, Vol.47, p.S6-S6

1998

Volltextzugriff (PDF)

2293 Localized prostate cancer: Health-related quality of life measurement and health status assessment following high dose rate brachytherapy and external beam radiation

International journal of radiation oncology, biology, physics, 1999, Vol.45 (3), p.430-431

1999

Volltextzugriff (PDF)

35 Do graphic dose-volume histograms give enough information about dose homogeneity and implant quality by using a stepping source?

Radiotherapy and oncology, 1996-05, Vol.39, p.S9-S9

1996

Volltextzugriff (PDF)

36 Paclitaxel/Carboplatin(TC) vs Paclitaxel/Carboplatin sequentially followed by Topotecan (TC-Top) in first-line treatment of ovarian cancer Flgo stages IIB – IV interim results of a gynaecologic cancer intergroup phase III trial of the Ago ovarian cancer study group and Gineco

European journal of cancer supplements, 2003-09, Vol.1 (5), p.S15-S15

2003

Volltextzugriff (PDF)

38 Influence of amifostine on neuroprotection in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy - a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group

European journal of cancer supplements, 2003-09, Vol.1 (5), p.S15-S16

2003

Volltextzugriff (PDF)

39 Topotecan versus treosulfan in recurrent ovarian cancer after initial chemotherapy with platinum and paclitaxel. a prospective randomised phase III study of the AGO ovarian cancer study group

European journal of cancer supplements, 2003-09, Vol.1 (5), p.S16-S16

2003

Volltextzugriff (PDF)

4 Ten years experience in organ preservation using HDR brachytherapy boost for nodal negative, locally advanced prostate cancer

Radiotherapy and oncology, 1996-05, Vol.39, p.S1-S1

1996

Volltextzugriff (PDF)

42 5-year results following conformal HDR brachytherapy (HDR CBT) and elective pelvic irradiation for high-risk prostate cancer (initial PSA > 20 ng/ml): Is hormonal therapy beneficial?

Radiotherapy and oncology, 2001, Vol.60, p.S14-S14

2001

Volltextzugriff (PDF)

1 – 25 von 783

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(683)
Mit Volltextzugriff
(518)

Publikationsform

Sprache

Englisch
(457)
Deutsch
(338)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

000197 THE ANTI-IDIOTYPIC MONOCLONAL ANTIBODY ACA125 IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PERITONEAL CANCER. A PHASE II TRIAL OF THE AGO-OVAR

0189: Influence of Platinum-Based Chemotherapy On Disseminated Tumor Cells in Blood and Bone Marrow of Patients with Primary Ovarian Cancer

105Development of version 2.0 prostate-specific instrument for standardized health-related quality of life (HR-QoL) measurement based on the experience with version 1.0 protocol: Reliability testing and main component analysis

1093 Local dose escalation using temporary interstitial source brachytherapy (high-dose-rate) for clinically localized prostate cancer: Long-term outcome in hormone naïve men

114 CARTILAGE BIOMARKERS AFTER ACLT

115 CARTILAGE BIOMARKERS AFTER MENISCECTOMY

1168P Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined

13-cis retinoic acid and interferon-alfa-2a as palliative therapy in pretreated, recurrent squamous epithelial carcinoma of the cervix uteri and vulva

13-cis Retinolsäure und interferon α2 a als Palliativtherapie beim vorbehandelten, rezidivierenden Plattenepithelkarzinom der Zervix uteri und Vulva

13-cis Retinolsäure und Interferon α2a als Palliativtherapie beim vorbehandelten, rezidivierenden Plattenepithelkarzinom der Zervix uteri und Vulva

154 O - Intermediate analysis at minimum 5 years follow-up of 70 patients with prostate cancer treated by external beam and brachytherapy

16 Orbital rhabdomyosarcoma of the child: The role of PDR brachytherapy in eye preservation

16 Peroperative eye-preserving interstitial PDR brachy-therapy (BT) for orbital tumors and malignancies involving the base of skull

162 Fractionated peroperative interstitial HDR/PDR-brachytherapy using the plastic tube technique and conformal treatment planning: The Kiel experience

172 Phase I/II study of PLD and carboplatin in patients with advanced gynaecological carcinomas. An interim analysis of the GYN II trial of the AGO ovarian cancer study group

173 Does non invasive nodal staging and elective irradiation of the pelvic lymphatics compromise the feasibility of local dose escalation using high dose rate brachytherapy for increased curability in men with localized prostate cancer? Long-term results: Survival and toxicity

2009 Prevalence of erectile dysfunction in men with prostate cancer (PCa) prior to definitive radiotherapy: a prospective assessment

21 Peroperative interstitial pdrfhdr-brachytherapy (BT) for rectal cancer recurrences or non curative resected primaries: Experience with 32 patients

2293 Localized prostate cancer: Health-related quality of life measurement and health status assessment following high dose rate brachytherapy and external beam radiation

35 Do graphic dose-volume histograms give enough information about dose homogeneity and implant quality by using a stepping source?

36 Paclitaxel/Carboplatin(TC) vs Paclitaxel/Carboplatin sequentially followed by Topotecan (TC-Top) in first-line treatment of ovarian cancer Flgo stages IIB – IV interim results of a gynaecologic cancer intergroup phase III trial of the Ago ovarian cancer study group and Gineco

38 Influence of amifostine on neuroprotection in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy - a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group

39 Topotecan versus treosulfan in recurrent ovarian cancer after initial chemotherapy with platinum and paclitaxel. a prospective randomised phase III study of the AGO ovarian cancer study group

4 Ten years experience in organ preservation using HDR brachytherapy boost for nodal negative, locally advanced prostate cancer

42 5-year results following conformal HDR brachytherapy (HDR CBT) and elective pelvic irradiation for high-risk prostate cancer (initial PSA > 20 ng/ml): Is hormonal therapy beneficial?

Suchergebnisse filtern